Masanori Atsukawa

Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial

Yoshiyuki Narahara, Hidenori Kanazawa, Takeshi Fukuda et al. · Journal of Gastroenterology · 2010 · 165 citations

Urology, Renal Function, Hepatology +8

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa et al. · Cancer Medicine · 2019 · 158 citations · Full text

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama et al. · Cancer Medicine · 2018 · 130 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 124 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

Oncology, Hepatology, Medicine +8